Article Text
Abstract
Background: HIV-positive patients treated for syphilis may be at increased risk for serological failure.
Objective: To compare follow-up serologies and serological responses to treatment between HIV-positive and HIV-negative patients attending two sexually transmitted disease (STD) clinics.
Study design: Existing records were reviewed from HIV-positive patients who were diagnosed and treated for syphilis at the public STD clinics in Baltimore, Maryland, USA, between 1992 and 2000. Results of their serological follow-up were compared with those of HIV-negative clinic patients at the time of syphilis treatment. Failure was defined as lack of a fourfold drop in rapid plasma reagin (RPR) titre by 400 days after treatment or a fourfold increased titre between 30 and 400 days.
Results: Of the 450 HIV-positive patients with syphilis, 288 (64%) did not have documented follow-up serologies and 129 (28.5%) met the inclusion criteria; 168 (17%) of 1000 known HIV-negative patients were similarly eligible. There were 22 failures in the HIV-positive group and 5 in the HIV-negative group (p<0.001). The median times to successful serological responses in both groups were 278 (95% confidence interval (CI) 209 to 350) and 126 (95% CI 108 to 157) days, respectively (p<0.001). A multivariate Cox’s proportional hazards model showed an increased risk of serological failure among the HIV-positive patients (hazards ratio 6.0, 95% CI 1.5 to 23.9; p = 0.01).
Conclusion: HIV-positive patients treated for syphilis may be at higher risk of serological failure. Despite recommendations for more frequent serological follow-up, most patients did not have documentation of serological response after standard treatment for syphilis.
- DIS, disease intervention specialist
- RPR, rapid plasma reagin
- STD, sexually transmitted disease
Statistics from Altmetric.com
Footnotes
-
Published Online First 30 August 2006
-
Funding: This study was supported by grant NIH 5R01AI045724 (to AMR).
-
Competing interests: None.
-
This paper was presented in part as an oral presentation at the International Society for Sexually Transmitted Diseases Research (ISSTDR), July 2005, Amsterdam, The Netherlands.
-
Ethical approval: This study was approved by the institutional review boards of the Johns Hopkins Medical Institutions and the Baltimore City Health Department, Baltimore, Maryland, USA.
-
Contributors: KGG: study design, data collection, data analysis, drafting of manuscript; EJE: study design, data collection, drafting of manuscript; ZSW: data collection; AMR: study design, data analysis, drafting of manuscript.